Michael A. Metzger - Sep 13, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President and COO, Director
Signature
/s/ Michael A. Metzger
Stock symbol
SNDX
Transactions as of
Sep 13, 2021
Transactions value $
-$726,833
Form type
4
Date filed
9/15/2021, 04:16 PM
Next filing
Sep 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $120K +16.7K +94.29% $7.20 34.3K Sep 13, 2021 Direct
transaction SNDX Common Stock Sale -$317K -16.7K -48.53% $19.02 17.7K Sep 13, 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $319K +44.3K +251.14% $7.20 62K Sep 14, 2021 Direct
transaction SNDX Common Stock Sale -$849K -44.3K -71.52% $19.15 17.7K Sep 14, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -16.7K -100% $0.00* 0 Sep 13, 2021 Common Stock 16.7K $7.20 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -44.3K -100% $0.00* 0 Sep 14, 2021 Common Stock 44.3K $7.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The sale prices ranged from $19.00 to $19.10
F3 The sale prices ranged from $19.00 to $19.31
F4 This option is fully vested.